CMVLF - Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript
2024-05-30 14:06:04 ET
Cellectis S.A. (CLLS)
Q1 2024 Earnings Conference Call
May 29, 2024, 08:00 AM ET
Company Participants
Arthur Stril - Interim-CFO
André Choulika - CEO
Mark Frattini - Chief Medical Officer
Conference Call Participants
Gena Wang - Barclays
Dev Prasad - Jefferies
Salveen Richter - Goldman Sachs
Jack Allen - Baird
Luisa Morgado - Van Lanschot Kempen
Kuan-Hung Lin - Wells Fargo
Presentation
Operator
Good morning, everyone, and welcome to the Cellectis First Quarter 2024 Earnings Call. [Operator Instructions] Please be aware that today's conference call is being recorded.
I'd now like to turn the conference over to your first speaker, Arthur Stril, Interim Chief Financial Officer. You may begin.
Arthur Stril
Good morning, and welcome, everyone, to Cellectis' first quarter 2024 corporate update and financial results conference call. Joining me on the call today are Dr. André Choulika, our Chief Executive Officer; and Dr. Mark Frattini, our Chief Medical Officer. Yesterday evening, Cellectis issued a 6-K in the press release reporting our financial statements for the three months' period ending March 31, 2024, and a corporate and business update. The report and press release are available on our website at cellectis.com.
As a reminder, we will make statements regarding Cellectis' financial outlook, including the sufficiency of cash to fund operations in addition to its manufacturing, regulatory and product development status as well as product development status of its license partners. These forward-looking statements, which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners, are subject to risks and uncertainties that may cause actual results to differ from those forecasted....
Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript